On February 24, 2021 Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, reported that it will host a call to discuss the Company’s strategic vision on Tuesday, March 2, 2021 at 10:00 a.m. ET (Press release, Epizyme, FEB 24, 2021, View Source [SID1234575555]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Next EPIsode: Rewriting Oncology Treatment with Epigenetics
Date: Tuesday, March 2, 2021
Time: 10:00 – 11:30 a.m. ET
Program:
Epizyme 2021 and Beyond
The Role of Epigenetics in Oncology
Tazverik Development: The Next Chapter
The Future of Epizyme’s Epigenetics Pipeline
A link to register for the event is available here. A live webcast of the event can also be accessed through the investor section of the Company’s website at www.epizyme.com, and will be archived for 60 days following the call.